

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 33/06, 31/38, 31/195, 31/19, 9/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/52579</b> <b>(43) International Publication Date:</b> 26 November 1998 (26.11.98)
<b>(21) International Application Number:</b> PCT/US98/10506 <b>(22) International Filing Date:</b> 22 May 1998 (22.05.98)  <b>(30) Priority Data:</b> 08/863,015 23 May 1997 (23.05.97) US 09/074,419 8 May 1998 (08.05.98) US  <b>(71) Applicant:</b> INSITE VISION INCORPORATED [US/US]; 965 Atlantic Avenue, Alameda, CA 94501 (US).  <b>(72) Inventors:</b> BOWMAN, Lyle, M.; 5135 Mount Tam Circle, Pleasanton, CA 94566 (US). PFEIFFER, James, F.; 2369 Thackery Drive, Oakland, CA 94611 (US). MEMARZADEH, Eric, B.; 574 Chestnut Street #6, San Carlos, CA 94070 (US). ROY, Samir; 7636 Northland Place, San Ramon, CA 94583 (US).  <b>(74) Agents:</b> FREED, Joel, M. et al.; Howrey & Simon, 1299 Pennsylvania Avenue, N.W., Box 34, Washington, DC 20004-2402 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> OPHTHALMIC COMPOSITIONS CONTAINING A DIVALENT SALT AND A NON STEROIDAL ANTI-INFLAMMATORY DRUGS AS A PRECIPITATE		
<b>(57) Abstract</b>  An ophthalmic composition containing a divalent salt and a non-steroidal anti-inflammatory agent as a precipitate. The composition reduces or eliminates the risk of stinging and burning the eye from topical application. Additionally a preservative system comprising a perborate salt, a polyphosphonic acid peroxy stabilizer and EDTA provides stable preservation of a variety of aqueous ophthalmic compositions.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

OPHTHALMIC COMPOSITIONS CONTAINING A DIVALENT SALT AND A NON STEROIDAL  
ANTI-INFLAMMATORY DRUGS AS A PRECIPITATE

5

## BACKGROUND OF THE INVENTION

### 1. Field of the Invention

The present invention relates to ophthalmic compositions and more  
10 particularly, to ophthalmic compositions containing a divalent cation and a non-steroidal anti-inflammatory agent and/or to ophthalmic compositions containing a preservative system.

### 2. Description of the Related Art

15 Non-steroidal anti-inflammatory agents can be used in a variety of ophthalmic treatments such as for treating ocular tissue inflammation and its associated pain. Additional uses include (i) preventing particular side-effects from surgical trauma (e.g., on the pupil preventing surgical meiosis), (ii) preventing fluid accumulation in the back of the eye after cataract surgery (post-surgical macular  
20 edema) and (iii) preventing the appearance of inflammatory cells and vessel leakage in the anterior chamber. Diclofenac, suprofen, and flurbiprofen are specific examples of non-steroidal anti-inflammatory agents that have been used for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Topical application of non-steroidal anti-inflammatory agents in the eye also appears  
25 to relieve some of the itching due to allergic conjunctivitis.

In the past, anti-inflammatory agents, in general, have been administered in solutions at neutral pH. Injection of anti-inflammatory agents in the form of a suspension has also been proposed. Suspensions have been used for topical ophthalmic applications when the drug is not very soluble. However, when the drug  
5 is soluble, at an acceptable pH, solutions are normally used to avoid potential irritation caused by the particles of the suspension. The following patents illustrate ophthalmic solutions containing non-steroidal anti-inflammatory agents, including diclofenac.

U.S. Patent No. 4,960,799 to Nagy concerns a storage stable aqueous  
10 solution of sodium ortho-(2,6-dichlorophenyl)aminophenylacetate acid, which is the chemical name for diclofenac sodium, for topical treatment of ocular inflammation. The solution taught by Nagy has a pH of about 7.0 to 7.8.

U.S. Patent No. 4,829,088 to Doulakas also relates to an ophthalmic medicament containing diclofenac sodium in aqueous solution. The solution contains  
15 2-amino-2-hydroxymethyl-1,3-propanediol as a preservative.

U.S. Patent No. 5,110,493 to Cherng-Chyi et al. relates to ophthalmic non-steroidal anti-inflammatory drug formulations containing a quaternary ammonium preservative and a non-ionic surfactant.

Patent Abstracts of Japan, Vol. 8, No. 7, Abs. Gp. C-204, concerning  
20 Japanese published application 58-174309 (pub. Oct. 13, 1983) relates to an antiphlogistic eye drop composition containing (1) a non-steroidal antiphlogistic agent having a carboxyl group in its structure and (2) a physiologically permissible calcium or magnesium salt. The salt is described as an irritation mitigating agent and is normally added in an amount of 1-1.5 mol per 1 mol of the non-steroidal agent.  
25 Sodium diclofenac is specifically mentioned as the non-steroidal antiphlogistic agent and the pH of the composition is preferably maintained in the 7-8 range.

However, a problem with the use of non-steroidal anti-inflammatory agents, as recognized in the above-mentioned Japanese published application, is that stinging or burning sensations are commonly experienced during the first few minutes after topical administration on the eye. Not only are patients who experience such stinging likely to avoid regularly taking their medication, they also receive less benefit from each application. Specifically, the stinging causes tearing which washes away the drug. Having physically removed a portion of the drug from the eye by tearing, the bioavailability of the drug is reduced.

In addressing the stinging problem, it has been proposed to supply a portion of the non-steroidal anti-inflammatory agent in suspension form, as is described in commonly assigned co-pending application serial number 08/248,500, filed May 24, 1994 (the entire contents of which are hereby incorporated by reference). The particle must dissolve before it can treat the eye. By providing some of the active agent as a particle, the flow of the drug onto the eye is delayed; i.e., providing some of the active agent as a particle reduces the initial concentration of the drug contacting the eye. This delay in drug delivery contrasted with the prior compositions wherein all of the agent was in solution, owing to a pH of 7 - 8, thereby immediately providing to the cornea a high concentration of the drug. The high concentration of the drug on the eye was believed to aggravate the burning and stinging effects of the drug.

While some improvements have been made with respect to the stinging problem by such a technique, there is still a segment of the population that will experience stinging when topically administering non-steroidal anti-inflammatory ophthalmic compositions. Accordingly, further improvements are desirable.

Additionally, preserving an ophthalmic composition that contains a non-steroidal anti-inflammatory agent can be problematic. Conventional broad

spectrum antimicrobial agents like benzalkonium chloride (BAK) tend to interact with the non-steroidal anti-inflammatory agents over time and thereby reduce the efficacy of the medication. Indeed, as a general matter, preservatives in ophthalmic compositions are not entirely satisfactory. Effective, broad spectrum antimicrobials  
5 tend to reduce the storage stability of the composition and/or have adverse interactions with other components.

A useful preservative system that seeks to overcome some of these deficiencies is disclosed in U.S. Patents 5,576,028 and 5,607,698. These systems use a low amount of hydrogen peroxide, or a hydrogen peroxide source, as a preservative  
10 in combination with a peroxy stabilizer. The stabilizer is preferably a phosphonic acid such as diethylene triamine penta(methylene-phosphonic acid) and the like which are commercially available from Monsanto under the DEQUEST brand name. Although this system is quite useful, certain improvements in storage stability would be desirable.

15

### SUMMARY OF THE INVENTION

It is an object of the present invention to provide an ophthalmic composition that contains a topically effective amount of a non-steroidal anti-  
20 inflammatory agent and that is no more irritating than conventional eye drops.

It is another object of the present invention to provide a non-steroidal anti-inflammatory agent-containing ophthalmic composition that can be taken by a large segment of the population without experiencing stinging or irritation.

A further object of the present invention is to provide a preserved  
25 ophthalmic composition that exhibits good stability during storage.

Another object of the present invention is to provide a method for treating diseases of the eye, including inflammation, by topically applying to eyes in need of such treatment a non-steroidal anti-inflammatory agent-containing ophthalmic composition.

5 Preferred forms of the invention contemplated accomplish at least some of the above objects. One embodiment of the invention is an ophthalmic composition comprising an aqueous medium containing an effective amount of a non-steroidal anti-inflammatory agent, wherein at least about 80 mol.% of said agent is in the form of a precipitate, and at least about 0.5 equivalents of a pharmacologically  
10 acceptable divalent cation per mole of said non-steroidal anti-inflammatory agent; said aqueous medium having a pH of from about 4.0 to 6.7. Another embodiment of the invention relates to a method for treating an eye, which comprises administering to an eye in need thereof an effective amount of such an ophthalmic composition. A further aspect of the present invention relates to a method for making such an  
15 ophthalmic composition. Another preferred embodiment of the present invention relates to an ophthalmic composition that is formed by combining at least (1) sodium diclofenac, (2) a divalent metal salt, (3) a water insoluble, water-swellaable polymer, and (4) water.

A further embodiment of the invention is an ophthalmic composition  
20 which comprises water, about 0.01 to 0.5 wt.% of a perborate salt, about 0.001 to 0.06 wt.% of a polyphosphonic acid peroxy stabilizer, and about 0.01 to 0.1 wt.% of ethylenediaminetetraacetic acid. The composition in this embodiment may further comprise a pharmaceutically active agent such as a non-steroidal anti-inflammatory agent.

25

### BRIEF DESCRIPTION OF THE DRAWING

Figure 1 shows the illustrious results of Example 21 regarding release rate curves for an inventive and a comparative ophthalmic composition.

### DETAILED DESCRIPTION OF THE INVENTION

5 The present inventors have discovered that by providing the non-steroidal anti-inflammatory (NSAI) agent as a solid and in the presence of a divalent cation, the dissolution of the NSAI agent during the first several minutes at neutral pH is sufficiently slowed so as to further avoid stinging the eye. For reasons that are not  
10 entirely clear, stinging and burning irritation are typically only induced during the first minutes after contact with a sufficiently high concentration of NSAI agent. After this initial time period, the eye is apparently no longer sensitive to the NSAI agent, regardless of its concentration level. Thus, by delaying the dissolution of the NSAI agent during the first few minutes, the initial NSAI agent concentration on the eye can  
15 be sufficiently low to avoid irritation. Afterward, the high concentration caused by the dissolution of the solid NSAI agent precipitate is too late to cause irritation. In this way the stinging problem is effectively avoided while still providing a topically effective dose of NSAI agent.

In contrast, the typical prior art composition would supply all of the  
20 NSAI agent as a solute and thus apply an immediate high concentration to the surface of the eye. Such a technique has the greatest chance of inducing stinging in the patient. While the use of sodium diclofenac in both suspension and solution form, simultaneously, is described in the above-mentioned co-pending application and provides good results, the presence of a divalent cation in accordance with the  
25 present invention improves the avoidance of stinging. The divalent cation reduces the solubility of the NSAI agent in the aqueous medium and thus reduces the dissolution



rate of the solid NSAI agent precipitate during the first several minutes after administration.

As used in this application, the term "divalent cation" means a cation having a +2 charge. The divalent cation can be in either solid or dissolved form, or both. In solid form, the cation is ionically bonded to an anion thereby making a salt. When in solution, the cation is not required to be directly associated with a specific anion. Typically the cation is, or contains, a metal; i.e., a "metal divalent cation". Examples of suitable divalent cations include Group IIA elements (alkaline earth metals) such as calcium, magnesium, barium, etc. Particularly preferred divalent cations are  $\text{Ca}^{++}$  and  $\text{Mg}^{++}$ . The divalent cation and any salts thereof in the composition are pharmacologically acceptable so as to not harm the eye or the patient. Typical anions include chlorides, sulfates, and the NSAI agent.

The divalent cation is only required to be present in the composition and is not necessarily associated or otherwise bonded with the NSAI agent. In one embodiment, all or essentially all of the divalent cation is in solution with no cation present in the solid NSAI agent.

The amount of divalent cation is at least about 0.5 equivalents and generally within the range of from about 0.5 to about 10 equivalents, more preferably 1.0 to about 5.0 equivalents, per mole of NSAI. Note that molar equivalents are specified since NSAI agents may be monovalent and hence stoichiometrically require only half as many moles of the divalent cation. Thus, for example, one mole of  $\text{Mg}^{++}$  per one mole of diclofenac anion would be 2.0 equivalents of  $\text{Mg}^{++}$  (twice as much cation as is required).

"Non-steroidal anti-inflammatory agents" as used herein are intended to mean any non-narcotic analgesic/non-steroidal anti-inflammatory compound useful in treating or ameliorating a disease or medical condition. They include drugs

intended to therapeutically treat conditions of the eye itself or the tissue surrounding the eye and drugs administered via the ophthalmic route to treat therapeutically a local condition other than that involving the eye. Preferably the NSAI agent is useful as a cyclooxygenase inhibitor. Cyclooxygenase is essential in the biosynthesis of  
5 prostaglandins which have been shown in many animal models to be mediators of intraocular inflammation. The NSAI agent typically contains at least one carboxy group in its molecule.

Examples of NSAI agents that are useful in the present invention include aspirin, benoxaprofen, benzofenac, bucloxic acid, butibufen, carprofen,  
10 cicloprofen, cinmetacin, clidanac, clopirac, diclofenac, etodolac, fenbufen, fenclofenac, fenclorac, fenoprofen, fentiazac, flunoxaprofen, furaprofen, flurbiprofen, furobufen, furofenac, ibuprofen, ibufenac, indomethacin, indoprofen, isoxepac, ketorolac, ketoprofen, lactorolac, lonazolac, metiazinic, miroprofen, naproxen, oxaprozin, oxepinac, phenacetin, pirprofen, pirazolac, protizinic acid, sulindac,  
15 suprofen, tiaprofenic acid, tolmetin, and zomepirac. Preferably, the NSAI agent is selected from the group consisting of diclofenac, suprofen, flurbiprofen and mixtures thereof.

The composition of the present invention contains at least 80% of the NSAI agent in precipitate form. This means that 80%, by mole, of the NSAI is in a  
20 solid state. The remainder, if any, is in solution. In this regard the term "precipitate" is not meant to require that the solid was formed by a precipitation process, although such is usually the case. Preferably, 85% to 95% of the NSAI agent is in precipitate form. The precipitate is usually dispersed in the aqueous medium or carried on a dispersed carrier such as a polymer particle, but such a dispersed form is not required.

25 In one embodiment of the invention, the precipitate is the free-acid form (or free-base form) and not a salt form of the NSAI agent. Generally, the free-

acid is almost always formed, even if formed from an NSAI divalent salt solution. For example, originally, a calcium or magnesium salt of diclofenac was believed to have been formed as the precipitate. However, subsequent investigations showed that the precipitate was in fact the free-acid of diclofenac. The divalent cation remained in solution. The presence of this divalent cation serves to reduce the solubility of the NSAI agent; thereby causing the desired delayed release. Alternatively, the precipitate can be a salt of the divalent cation and the NSAI agent or a mixture of salt and the free-acid forms.

The remaining portion, if any, of the NSAI agent is in solution (a solute) and is typically in a salt form such as sodium diclofenac or magnesium diclofenac for example.

The total amount of NSAI agent present in the composition is an amount effective to treat the selected target condition. Generally the concentration will be about 0.001 to about 5.0% by weight of the composition. Preferably, the drug is about 0.005 to about 3.0% by weight of the composition, and more preferably about 0.1 to about 1.0% by weight of the composition. These same ranges of drug concentrations are believed to be appropriate for treating a wide range of conditions, such as those discussed above, in addition to treating inflammation.

The pH of the aqueous medium is set to be within the range of 4.0 to 6.7. Importantly the pH is below that of the pH of the eye. In this way, upon topical application of the composition to the eye, an increase in pH occurs thereby changing the solubility equilibrium of the NSAI agent and causing the precipitate to dissolve. As slow dissolution during the first minutes after administration is desired, the use of a lower pH is preferred, such as from 4.0 to 6.5.

The most preferred composition contains solid diclofenac in free-acid form and all of the divalent cation as well as the remaining diclofenac in solution.

The divalent cation is preferably calcium or magnesium. One of the advantages of this composition is the ability to fully (100%) redissolve at pH 7.0 or above with adequate residence time in the eye. This means that all of the diclofenac is recovered and made bioavailable when the composition is placed into the eye.

5               The aqueous medium used in the present invention is made of water that has no physiologically or ophthalmologically harmful constituents. Typically purified or deionized water is used. The pH is adjusted by adding any physiologically and ophthalmologically acceptable pH adjusting acids, bases or buffers. Examples of acids include acetic, boric, citric, lactic, phosphoric, hydrochloric, and the like, and  
10   examples of bases include sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate, tromethamine, THAM (trishydroxymethylamino-methane), and the like. Salts and buffers would include citrate/dextrose, sodium bicarbonate, ammonium chloride and mixtures of the aforementioned acids and bases.

15               The osmotic pressure ( $\pi$ ) of the present composition is preferably from about 10 milliosmolar (mOsM) to about 400 mOsM. If necessary, the osmotic pressure can be adjusted by using appropriate amounts of physiologically and ophthalmologically acceptable salts or excipients. When needed, sodium chloride is preferred to approximate physiologic fluid, and amounts of sodium chloride ranging  
20   from about 0.01% to about 1% by weight, and preferably from about 0.05% to about 0.45% by weight, based on the total weight of the composition, are typically used. Equivalent amounts of one or more salts made up of cations such as potassium, ammonium and the like and anions such as chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate, bisulfate, sodium bisulfate, ammonium  
25   sulfate, and the like can also be used in addition to or instead of sodium chloride to

achieve osmolalities within the above-stated range. Sugars like mannitol, dextrose, glucose or other polyols may be added to adjust osmolarity.

The composition of the present invention may contain water soluble polymers or water insoluble polymers as a suspending agent. Examples of such soluble polymers are dextran, polyethylene glycols, polyvinylpyrrolidone, polysaccharide gels, Gelrite®, and cellulosic polymers like hydroxypropyl methylcellulose as well as other polymeric demulcents. Water insoluble polymers are preferably crosslinked carboxy-vinyl polymers.

A preferred embodiment of the invention provides the ophthalmic composition as either gel or liquid drops that contain water insoluble, water-swella-  
ble polymers which release the drug over time; i.e., over one or more hours. Preferably, the polymer is contained in an amount of about 0.1 to about 6.5%, more preferably about 0.5 to about 1.3% by weight based on the total weight of the composition. These polymer carriers include lightly crosslinked carboxy-containing polymers (such as polycarbophil (Noveon AA-1) or Carbopol®) which typically have an average dry particle size of not more than about 50µm in equivalent spherical diameter, more preferably not more than 20µm in equivalent spherical diameter. The crosslinked carboxy-containing polymers can be formed from carboxy-containing monoethylenically unsaturated monomers such as acrylic acid, methacrylic acid, crotonic acid, and the like and from suitable crosslinking agents such as difunctional crosslinkers including divinyl glycol, divinyl benzene, 2,5-dimethyl-1,5-hexadiene, and polyalkenyl polyether compounds. The carboxy-containing polymer backbone can be a homopolymer or a copolymer comprised of two or more monomer species. When two or more monomers are used, non-carboxy-containing monomers may be employed, such as acrylic acid esters and methacrylic acid esters (ethyl acrylate, methyl methacrylate, etc.), vinyl acetate, N-vinylpyrrolidone, and the like. These non-

carboxy-containing comonomers are preferably present in an amount of not more than 40 wt.%, more preferably 0 to 20 wt.%, based on the total weight of monomers present. The amount of crosslinker employed is preferably from about 0.01 to 5%, more preferably from 0.1 to 1.0%, based on the total weight of monomers present.

5 Suitable carboxy-containing polymers for use in the present invention and methods for making them are described in U.S. Patent No. 5,192,535 to Davis et al. which is hereby incorporated by reference. A suitable carboxy-containing polymer system for use in the present composition is known by the tradename DuraSite®, containing polycarbophil, which is a sustained release topical ophthalmic delivery system that  
10 releases the drug at a controlled rate.

The ophthalmic compositions of the present invention have a viscosity that is suited for the selected route of administration. A viscosity up to about 30,000 centipoise is useful for a drop. About 30,000 to about 100,000 centipoise is an advantageous viscosity range for ophthalmic administration in ribbon form. The  
15 viscosity can be controlled in many ways known to the worker skilled in the art.

In one embodiment, the amount of insoluble lightly crosslinked polymer particles, the pH, and the osmotic pressure can be correlated with each other and with the degree of crosslinking to give a composition having a viscosity in the range of from about 500 to about 100,000 centipoise, and preferably from about 1,000  
20 to about 30,000 or about 1,000 to about 10,000 centipoise, as measured at room temperature (about 25° C) using a Brookfield Digital LVT Viscometer equipped with a number 25 spindle and a 13R small sample adapter at 12 rpm. Alternatively, when water soluble polymers are used, such as hydroxypropyl methylcellulose, the viscosity will typically be about 10 to about 400 centipoise, more typically about 10 to about  
25 200 centipoises or about 10 to about 25 centipoise.

Ophthalmic compositions of the present invention may be formulated so that they retain the same or substantially the same viscosity in the eye that they had prior to administration to the eye. Alternatively, ophthalmic compositions of the present invention may be formulated so that there is increased gelation upon contact with tear fluid. For instance, when a formulation containing DuraSite® is administered to the eye at a lower pH, the DuraSite® system swells upon contact with tears. This gelation or increase in gelation leads to entrapment of the suspended drug particles, thereby extending the residence time of the composition in the eye. The drug is released slowly as the suspended particles dissolve over time as the solubility of the drug is higher in the tear fluid. All these events eventually lead to increased patient comfort, increase in the time the drug is in contact with the eye tissues, thereby increasing the extent of drug absorption and duration of action of the formulation in the eye.

The viscous gels that result from fluid eye drops typically have residence times in the eye ranging from about 2 to about 12 hours, e.g., from about 3 to about 6 hours. The agents contained in these drug delivery systems will be released from the gels at rates that depend on such factors as the drug itself and its physical form, the extent of drug loading and the pH of the system, as well as on any drug delivery adjuvants, such as ion exchange resins compatible with the ocular surface, which may also be present. Preferably, the compositions provide a sustained concentration of the NSAID agent of between  $10^{-8}$  and  $10^{-4}$  M, and more preferably between  $10^{-7}$  and  $10^{-5}$  M, in the aqueous or treated tissue of the eye for at least two hours, preferably at least three hours.

The composition of the present invention will ordinarily contain surfactants and, if desired, adjuvants, including additional medicaments, buffers, antioxidants, tonicity adjusters, preservatives, thickeners or viscosity modifiers, and

the like. Additives in the formulation may desirably include sodium chloride, EDTA (disodium edetate), phosphonic acid, BAK (benzalkonium chloride), perborate salt, sorbic acid, methyl paraben, propyl paraben, and/or chlorhexidine. It should be noted that BAK was found to be unexpectedly compatible with diclofenac in the present  
5 ophthalmic composition. While the reasons for this are not entirely clear, and without wishing to be bound by any theory, the presence of the divalent cation is believed to prevent the BAK from complexing the diclofenac out of the system.

The preferred preservative in the divalent cation non-steroidal anti-inflammatory ophthalmic composition is sodium perborate in an amount of from  
10 about 0.01 to 0.5 wt.%, more preferably from 0.03 to 0.3 wt.%.


In this connection, applicants have also discovered that a perborate salt can be effectively stabilized by the presence of both a polyphosphonic acid peroxy stabilizer and EDTA. This discovery was surprising in that the presence of EDTA would have been expected to interfere with the complexing action of the  
15 polyphosphonic acid stabilizer. Moreover, the presence of EDTA surprisingly enhances the stability of the composition. This three component preservative system is applicable to any aqueous ophthalmic composition including saline solutions, eye lubricants, medicated compositions, etc. and is not limited to use in combination with a non-steroidal anti-inflammatory agent. The preservative system comprises (1) about  
20 0.01 to 0.5 wt.%, preferably 0.03 to 0.3 wt.%, of a perborate salt; (2) about 0.001 to 0.06 wt.%, preferably 0.003 to 0.3 wt.%, of a polyphosphonic acid peroxy stabilizer; and (3) about 0.01 to 0.1 wt.% of EDTA, based on the total weight of the composition. The preservative system may additionally comprise 0.05 to 0.2 parts of BAK. The perborate salt is preferably sodium perborate.

25 A "polyphosphonic acid peroxy stabilizer" means any compound containing at least two  $-PO_3H_2$  moieties or the pharmacologically acceptable salt




thereof, and that is capable of stabilizing a peroxy compound. Such compounds are generally well known in the prior art. Preferably the polyphosphonic acid peroxy stabilizer is a compound of the formula I or II or a pharmacologically acceptable salt thereof:

5



wherein  $x$  is an integer of 0 to 3 and  $k$ ,  $m$ ,  $n$ ,  $o$ , and  $p$  are each independently an integer of 1 to 4. Preferably  $x$  is 2 and  $k$ ,  $m$ ,  $n$ ,  $o$ , and  $p$  are each 1 or 2.

10



wherein  $q$ ,  $r$ ,  $s$ , and  $t$  are each independently an integer of 0 to 4. Preferably  $q$ ,  $r$ ,  $s$ , and  $t$  are 0 or 1, and most preferably all are zero.

15

Many of the compounds of formulas I and II are sold by Monsanto under the DEQUEST brand name. A preferred compound is diethylene triamine

penta(methylene-phosphonic acid), which corresponds to formula I, and is sold as DEQUEST 2060.

The water used in the preserved ophthalmic composition of the present invention is normally sterilized. The preserved ophthalmic composition can contain  
5 additional ingredients including any of the ingredients discussed previously. For example, sodium chloride can be present as part of a saline solution; a carboxy-containing polymer, such as polycarbophil, can be present to form a stably preserved suspension; etc. With respect to the latter composition, a preferred form further includes magnesium ions ( $Mg^{++}$ ) in addition to the polymer and the  
10 perborate/polyphosphonic acid peroxy stabilizer/EDTA system. The amount of magnesium is not particularly limited, but typically ranges from about 0.005 to 0.5wt.%, preferably 0.02 to 0.2 wt.% (the amount of polymer being the same as described above). Such a composition is well preserved and also exhibits a stable viscosity during storage.

15 Alternatively, a pharmaceutically active agent may be present as part of a medicated composition. In this regard, a "pharmaceutically active agent" is broader in scope than an NSAID agent and embraces any agent with pharmaceutical utility that can be used to treat the eye or administered via the eye in treating a disease or condition of the patient.

20 The preservative system can be used in a variety of aqueous ophthalmic compositions such as saline solutions for cleaning contact lenses, as an eye wash, as an eye lubricating or wetting composition, and as a medicated composition. The preservative system of the present invention is preferably combined with the above-described divalent cation-containing ophthalmic composition.

25 The compositions of the present invention can be prepared from known materials through the application of known techniques by workers of ordinary

skill in the art without undue experimentation. In general, compositions are formed by combining the NSAI agent, a divalent cation source, optionally a polymer, and water. In one embodiment, the divalent cation is first completely dissolved in an aqueous solution, adjusting the pH or temperature if necessary. The divalent cation source is typically in the form of a salt, but any water soluble form is acceptable. Preferred divalent cation sources are divalent metal salts such as  $\text{CaCl}_2$ ,  $\text{MgCl}_2$  and  $\text{MgSO}_4$ . The NSAI agent is then added, typically in the form of a salt although such is not required, resulting in precipitation of the NSAI agent. Generally the precipitation will be immediate without adjustment of the solution. However, aids in causing precipitation, such as seeding, may also be used, either alone, or in addition to pH modifiers, in order to encourage or enhance precipitate formation.

After the precipitation of the NSAI agent, the polymer, if any, can be added to the aqueous composition by conventional techniques. The resulting composition is sterilized and then the remaining ingredients such as buffers, surfactants, etc. are added thereto. It is not preferred to heat sterilize after the precipitate is formed in that redissolving and recrystallization of the precipitate can occur and may adversely effect the precipitate, e.g. increasing the crystal size. Alternatively, the precipitate-containing solution can be combined with a sterilized aqueous polymer dispersion, optionally containing buffer, surfactant, preservative and/or other ingredients.

In another embodiment, the NSAI agent is added to a solution that contains the divalent cation source and optionally a dispersed polymer to form the precipitate-containing composition. The solution can be previously sterilized and preferably contains all ingredients except the NSAI agent (and possibly a final portion of water) at the time of NSAI agent addition.

If a carboxy-containing polymer is to be added to the composition, then the amount of free divalent cation added should be controlled so as not to significantly exceed the stoichiometric amount. Specifically, a large excess of free calcium, magnesium, divalent cations, etc., could react with and complex the polymer thereby disrupting the suspension and preventing the release of the NSAID agent. Alternatively a chelating agent such as EDTA should be provided in the composition in order to chelate any excess divalent cation (e.g., calcium, magnesium, etc.). Such a chelating agent can be provided in the dispersed polymer-containing solution, if desired. The amount of chelating agent depends in part on the amount of NSAID agent and divalent cation source and need only be sufficient to avoid the above-mentioned disruption.

Although the above described methods are suitable for making the present ophthalmic composition, they are not the only methods. Other methods for making the present composition can be used.

The ophthalmic compositions according to the present invention can be topically administered in accordance with techniques familiar to persons skilled in the art. The finished formulations are preferably stored prior to use in opaque or brown containers to protect them from light exposure, and under an inert atmosphere. These compositions can be packaged in preservative-free, single-dose non-reclosable containers. This permits a single dose of the medicament to be delivered to the eye as a drop or ribbon, with the container then being discarded after use. Such containers eliminate the potential for preservative-related irritation and sensitization of the corneal epithelium, as has been observed to occur particularly from ophthalmic medicaments containing mercurial preservatives. Multiple dose containers can also be used, if desired, particularly since relatively low viscosities can be obtained in

compositions of the invention which permit constant, accurate dosages to be administered dropwise to the eye as many times each day as necessary.

The following non-limiting example serves to illustrate certain features of the present invention.

5

### EXAMPLES 1-5

Hydrated polymer is prepared by adding 2.3 grams of polycarbophil or 2.4 grams of Carbopol ®974P to 100 grams of purified water in a 600 ml beaker and mixing for 30 minutes with an overhead stirrer. Then, 0.2 gram of edetate disodium is added and mixed for 5 minutes followed by 1 gram of sodium chloride, which is also mixed for 5 minutes. In a separate 50 ml beaker, different amounts of poloxamer 407 is dissolved in 15 grams of purified water. The solution is then added to the polycarbophil or Carbopol dispersion and mixed for 5 minutes. After adjusting the pH of the dispersion to 4 using 2N sodium hydroxide, it is sterilized by autoclaving at 121°C for 20 minutes. The drug solution is prepared by combining, in a separate 100 ml beaker, different amounts of diclofenac sodium, 2 grams of mannitol and various amounts of CaCl<sub>2</sub> dihydrate in 40 grams of purified water. The resulting suspension is then added to the polycarbophil or Carbopol dispersion and mixed for 15 minutes. The formulation is neutralized by adjusting the pH of the formulation to 6.0 using 2N sodium hydroxide. This causes it to gel. Finally, the weight of the solution is brought to 200 grams by adding purified water.

TABLE 1				
Amount Of Each Component Added to make the Formulations of Examples 1-4				
Ingredients	Example 1 Wt. %	Example 2 Wt. %	Example 3 Wt. %	Example 4 Wt. %
polycarbophil	1.15	1.15	1.15	1.15
edetate disodium	0.1	0.1	0.1	0.1
sodium chloride	0.5	0.5	0.5	0.5

diclofenac sodium	0.1	0.3	0.1	0.3
calcium chloride dihydrate	0.0173	0.0519	0.0208	0.0623
poloxamer 407	0.05	0.1	0.05	0.1
mannitol	1.0	1.0	1.0	1.0
purified water q.s.	100	100	100	100

Amount of Each Component Added to make the Formulation of Example 5	
Ingredients	Example 5 Wt. %
Carbopol ®974P	1.2
edetate disodium	0.1
sodium chloride	0.5
diclofenac sodium	0.1
calcium chloride dihydrate	0.0173
poloxamer 407	0.05
mannitol	1.0
purified water q.s.	100

#### EXAMPLES 6-9

- 5                    Hydrated polycarbophil (Noveon AA-1) is prepared by adding 2.3 grams of polycarbophil to 100 grams of purified water in a 600 ml beaker and mixing for 30 minutes with an overhead stirrer. Then 0.2 gram of edetate disodium is added and mixed for 5 minutes followed by 1 gram of sodium chloride mixed for 5 minutes. In a separate 50 ml beaker, different amounts of poloxamer 407 (a commercially
- 10                    available surfactant) is dissolved in 15 grams of purified water. The solution is then added to polycarbophil dispersion and mixed for 5 minutes. After adjusting the pH of the dispersion to 4 using 2N sodium hydroxide, it is sterilized by autoclaving at 121°C for 20 minutes. The drug solution is prepared by combining, in a separate 100 ml beaker, different amounts of diclofenac sodium, 2 grams of mannitol and various
- 15                    amounts of magnesium sulfate heptahydrate in 40 grams of purified water. The resulting suspension is then added to the polycarbophil dispersion and mixed for 15 minutes. The formulation is neutralized by adjusting the pH of the formulation to 6.0

using 2N sodium hydroxide. This causes it to gel. Finally, the weight of the solution is brought to 200 grams by adding purified water. The amount of each component in Examples 5-8 is listed in Table 2.

<b>TABLE 2</b>				
Amount Of Each Component Added to Make the Formulations of Examples 6-9				
Ingredients	Example 6 Wt. %	Example 7 Wt. %	Example 8 Wt. %	Example 9 Wt. %
polycarbophil	1.15	1.15	1.15	1.15
edetate disodium	0.1	0.1	0.1	0.1
sodium chloride	0.5	0.5	0.5	0.5
diclofenac sodium	0.1	0.3	0.1	0.3
magnesium sulfate heptahydrate	0.0387	0.116	0.0464	0.139
poloxamer 407	0.05	0.1	0.05	0.1
mannitol	1.0	1.0	1.0	1.0
purified water q.s.	100	100	100	100

5

### **EXAMPLES 10-13**

Hydrated polycarbophil (Noveon AA-1) is prepared by adding 1.6 grams of polycarbophil to 100 grams of purified water in a 600 ml beaker and mixing for 30 minutes with an overhead stirrer. Then 0.2 gram of edetate disodium is added and mixed for 5 minutes followed by 1 grams of sodium chloride mixed for 5 minutes. In a separate 50 ml beaker, 0.02 grams of benzalkonium chloride is dissolved in 20 grams of purified water. The solution is then added to the polycarbophil dispersion and mixed for 5 minutes. In a separate 50 ml beaker, different amounts of poloxamer 407 is dissolved in 15 grams of purified water. The solution is then added to polycarbophil dispersion and mixed for 5 minutes. After adjusting the pH of the dispersion to 4 using 2N sodium hydroxide, it is sterilized by autoclaving at 121°C for 20 minutes. The drug solution is prepared by combining, in a separate 100 ml beaker, different amounts of diclofenac sodium, 3.0 grams of

10

15

- sorbitol, 0.4 grams of glycerin and various amounts of calcium chloride dihydrate in 40 grams of purified water. The resulting suspension is then added to the polycarbophil dispersion and mixed for 15 minutes. The formulation is neutralized by adjusting the pH of the formulation to 6.0 using 2N sodium hydroxide. This
- 5 causes it to gel. Finally, the weight of the solution is brought to 200 grams by adding purified water. The amount of each component in Examples 9-12 is listed in Table 3.

TABLE 3				
Amount Of Each Component Added to Make the Formulations in Examples 10-13				
Ingredients	Example 10 Wt. %	Example 11 Wt. %	Example 12 Wt. %	Example 13 Wt. %
polycarbophil	0.8	0.8	0.8	0.8
edetate disodium	0.1	0.3	0.1	0.1
sodium chloride	0.25	0.25	0.25	0.25
diclofenac sodium	0.1	0.3	0.1	0.3
calcium chloride dihydrate	0.0173	0.0519	0.0208	0.0623
benzalkonium chloride	0.01	0.01	0.01	0.01
poloxamer 407	0.05	0.1	0.05	0.1
glycerin	0.2	0.2	0.2	0.2
sorbitol	1.5	1.5	1.5	1.5
purified water q.s.	100	100	100	100

10

**EXAMPLES 14-17**

- Hydrated polycarbophil (Noveon AA-1) is prepared by adding 1.6 grams of polycarbophil to 100 grams of purified water in a 600 ml beaker and mixing for 30 minutes with an overhead stirrer. Then 0.2 gram of edetate disodium is added and mixed for 5 minutes followed by 1 grams of sodium chloride mixed for 5
- 15 minutes. In a separate 50 ml beaker, 0.02 grams of benzalkonium chloride is dissolved in 20 grams of purified water. The solution is then added to the polycarbophil dispersion and mixed for 5 minutes. In a separate 50 ml beaker, different amounts of poloxamer 407 is dissolved in 15 grams of purified water. The



solution is then added to polycarbophil dispersion and mixed for 5 minutes. After adjusting the pH of the dispersion to 4 using 2N sodium hydroxide, it is sterilized by autoclaving at 121°C for 20 minutes. The drug solution is prepared by combining, in a separate 100 ml beaker, different amounts of diclofenac sodium, 3.0 grams of sorbitol, 0.4 grams of glycerin and various amounts of calcium chloride dihydrate in 40 grams of purified water. The resulting suspension is then added to the polycarbophil dispersion and mixed for 15 minutes. The formulation is neutralized by adjusting the pH of the formulation to 6.0 using 2N sodium hydroxide. This causes it to gel. Finally, the weight of the solution is brought to 200 grams by adding purified water. The amount of each component in Examples 13-16 is listed in Table 4.

TABLE 4				
Amount Of Each Component Added to Make the Formulations of Examples 14-17				
Ingredients	Example 14 Wt. %	Example 15 Wt. %	Example 16 Wt. %	Example 17 Wt. %
polycarbophil (Noveon AA-1)	0.8	0.8	0.8	0.8
edetate disodium	0.1	0.3	0.1	0.1
sodium chloride	0.25	0.25	0.25	0.25
diclofenac sodium	0.1	0.3	0.1	0.3
magnesium sulfate heptahydrate	0.0387	0.116	0.0464	0.139
benzalkonium chloride	0.01	0.01	0.01	0.01
poloxamer 407	0.05	0.1	0.05	0.1
glycerin	0.2	0.2	0.2	0.2
sorbitol	1.5	1.5	1.5	1.5
purified water q.s.	100	100	100	100

#### EXAMPLES 18-19

Hydrated polycarbophil (Noveon AA-1) is prepared by adding 1.6 grams of polycarbophil to 100 grams of purified water in a 600 ml beaker and mixing for 30 minutes with an overhead stirrer. Then 0.2 gram of edetate disodium is added

and mixed for 5 minutes followed by 1 grams of sodium chloride mixed for 5 minutes. In a separate 50 ml beaker, 0.02 grams of benzalkonium chloride is dissolved in 20 grams of purified water. The solution is then added to the polycarbophil dispersion and mixed for 5 minutes. In a separate 50 ml beaker, 5 different amounts of poloxamer 407 is dissolved in 15 grams of purified water. The solution is then added to polycarbophil dispersion and mixed for 5 minutes. After adjusting the pH of the dispersion to 4 using 2N sodium hydroxide, it is sterilized by autoclaving at 121°C for 20 minutes. The drug solution is prepared by combining, in a separate 100 ml beaker containing 40 grams of purified water, Suprofen or 10 Flurbiprofen sodium, 3.0 grams of sorbitol, 0.4 grams of glycerin and an amount of either magnesium sulfate heptahydrate or calcium chloride dihydrate sufficient to form a precipitate of the drug. The resulting suspension is then added to the polycarbophil dispersion and mixed for 15 minutes. The formulation is neutralized by adjusting the pH of the formulation to 6.0 using 2N sodium hydroxide. This 15 causes it to gel. Finally, the weight of the solution is brought to 200 grams by adding purified water.

#### **EXAMPLE 20**

Hydrated hydroxypropyl methyl cellulose (HPMC) is prepared by 20 adding 2.0 grams of HPMC to 100 grams of purified water in a 600 ml breaker and mixing for 4 hours with an overhead stirrer. Then, 1 gram of sodium chloride, 0.242 grams of dibasic sodium phosphate and 0.055 grams of monobasic sodium phosphate are added and mixed for 5 minutes. In a separate 50 ml beaker, 0.02 grams of benzalkonium chloride is dissolved in 20 grams of purified water. The solution is 25 then added to the HPMC dispersion and mixed for 5 minutes. In a separate 50 ml beaker, different amounts of poloxamer 407 is dissolved in 15 grams of purified water. The solution is then added to the HPMC dispersion and mixed for 5 minutes.

It is sterilized by autoclaving at 121 °C for 20 minutes. The drug solution is prepared by combining, in a separate 100 ml beaker containing 40 grams of purified water, either Diclofenac sodium, Suprofen or Flurbiprofen sodium with 3.0 grams of sorbitol, 0.4 grams of glycerin and an amount of either magnesium sulfate heptahydrate or calcium chloride dihydrate sufficient to form a precipitate of the drug. The resulting suspension is then added to the HPMC dispersion and mixed for 15 minutes. The formulation is neutralized by adjusting the pH of the formulation to 6.0 using 2N sodium hydroxide. Finally, the weight of the solution is brought to 200 grams by adding purified water.

10

**EXAMPLE 21**

To demonstrate the surprising effect of the present invention, two ophthalmic compositions are prepared, which essentially differ from each other with respect to the presence or absence of a divalent cation. Composition A, made in accordance with the present invention, includes the presence of a divalent cation (Mg<sup>++</sup>). Comparative Composition B does not have a divalent cation, but does have a monovalent cation (Na<sup>+</sup>) and is similar to the exemplified compositions set forth in the above-mentioned co-pending application serial number 08/248,500, filed May 24, 1994. The compositions are prepared from the ingredients listed in the table below.

Ingredient	Composition A (wt.%)	Composition B (wt.%)
Diclofenac sodium	0.033	0.033
Magnesium chloride	0.2	--
Sodium chloride	--	0.5
Sodium perborate	0.28	--
Polycarbophil	0.7	1.15
Phosphonic acid (Dequest 2060)	0.006	--
EDTA	--	0.1
Mannitol	1.5	1.0
Boric acid	0.75	--
Poloxamer 407	0.05	0.05

Sodium hydroxide	q.s. to pH 6.1	q.s. to pH 6.0
Purified water	q.s. to 100	q.s. to 100

Each composition is tested to determine its release rate over time. Samples are placed into a buffer solution contained in a cell. The cell size is 0.6 ml and the buffer is a phosphonate buffered saline solution containing 0.9% NaCl and 10mM phosphate at pH 7.4. Additional buffer is then steadily passed through the cell via a peristaltic pump at an appropriate rate to model natural liquid turnover in the eye; here 6ml/hr. The temperature is maintained at approximately 37°C (body temperature). The concentration of the medicament in the eluted buffer is measured over time by spectroscopy, to thereby form a release rate curve. Illustrous results are depicted in figure 1.

The release rate curve shown for composition A according to the present invention shows a delay in the initial release. In contrast, the release rate curve shown for composition B displays a higher peak during the initial release. Thus, the composition according to the present invention provides for improved delayed release during the important initial contact period with the eye and thereby reduces the tendency of stinging.

#### Example 22

Further embodiments of the present invention are obtained by combining the ingredients set forth in the following table.

Ingredient	Composition 22A (wt.%)	Composition 22B (wt.%)
Sodium diclofenac	0.03 to 0.1	0.03 to 0.1
Magnesium chloride hexahydrate	0.02 to 0.2	0.02 to 0.2
Sodium perborate	0.28	0.28
BAK	--	0.01
Polycarbophil	0.825	0.825
Dequest 2060	0.006	0.006
EDTA	0.025	0.025

Mannitol	1.5	1.5
Sodium chloride	0.05	0.05
Boric acid	1.0	1.0
Poloxamer 407	0.05	0.05
Sodium hydroxide	q.s. to pH 6.1	q.s. to pH 6.1
Purified water	q.s. to 100	q.s. to 100

The ingredients, except for the sodium diclofenac, are preferably combined so as to form a polymer suspension. Then the sodium diclofenac is added  
5 resulting in the precipitation of the diclofenac free-acid. A final portion of water is then added to complete the composition.

The above discussion of this invention is directed primarily to preferred embodiments and practices thereof. It will be readily apparent to those skilled in the art that further changes and modifications in actual implementation of  
10 the concepts described herein can easily be made or may be learned by practice of the invention, without departing from the spirit and scope of the invention as defined by the following claims.

We claim:

1. An ophthalmic composition comprising an aqueous medium containing an effective amount of a non-steroidal anti-inflammatory agent, wherein at least about 80 mol.% of said agent is in the form of a precipitate, and at least about 0.5 mole equivalents of a pharmacologically acceptable divalent cation per mole of said non-steroidal anti-inflammatory agent precipitate; said aqueous medium having a pH in the range of from 4.0 to 6.7.
2. The composition according to claim 1, wherein said non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac, suprofen, and flurbiprofen.
3. The composition according to claim 2, wherein said non-steroidal anti-inflammatory agent is diclofenac.
4. The composition according to claim 1, wherein said pharmacologically acceptable divalent cation is a Group IIA metal.
5. The composition according to claim 4, wherein said Group IIA divalent metal cation is calcium or magnesium.
6. The composition according to claim 1, wherein said precipitate is in a free-acid form.
7. The composition according to claim 6, wherein said divalent cation is present as a solute in said aqueous medium.

8. The composition according to claim 7, wherein said divalent cation is present from 1 to 5 times the stoichiometric amount equivalent to the molar amount of said non-steroidal anti-inflammatory agent precipitate.

9. The composition according to claim 8, wherein 85 to 95% of said non-steroidal anti-inflammatory agent is in said precipitate form.

10. The composition according to claim 9, wherein said NSAID agent is diclofenac and said divalent cation is  $Mg^{++}$ .

11. The composition according to claim 1, further comprising a polymer.

12. The composition according to claim 11, wherein said polymer is water insoluble and water swellable.

13. The composition according to claim 12, wherein said polymer is a crosslinked carboxy-containing polymer.

14. The composition according to claim 13, wherein said polymer is a polycarbophil.

15. The composition according to claim 13, wherein said polymer is a Carbopol.

16. The composition according to claim 15, wherein said polymer is Carbopol 974P

17. The composition according to claim 13, further comprising EDTA.

18. The composition according to claim 1, wherein said aqueous medium has a pH of from 4.0 to 6.5.
19. The composition according to claim 1, wherein said non-steroidal anti-inflammatory agent is contained in an amount of from 0.01 to 5.0% by weight of the entire composition.
20. The composition according to claim 1, further comprising a perborate salt.
21. A method for treating an eye, which comprises administering to an eye in need thereof an effective amount of the composition according to claim 1.
22. A method for making the composition according to claim 1, which comprises:  
combining a non-steroidal anti-inflammatory agent and a divalent cation source in an aqueous medium to form a precipitate-containing solution.
23. The method according to claim 22, wherein said non-steroidal anti-inflammatory agent is added to an aqueous solution containing a polymer dispersed therein and said divalent cation source.
24. The method according to claim 23, wherein said aqueous solution further comprises EDTA and said dispersed polymer is a water insoluble, water-swellaable crosslinked carboxy-containing polymer.
25. The method according to claim 24, wherein said non-steroidal anti-inflammatory agent comprises diclofenac and said divalent cation source is  $\text{CaCl}_2$ ,  $\text{MgCl}_2$  or  $\text{MgSO}_4$ .




26. An ophthalmic composition obtained by combining at least (1) sodium diclofenac, (2) a divalent metal salt, (3) a water insoluble, water-swellaable polymer, and (4) water.
27. The composition according to claim 26, which further comprises EDTA and wherein said divalent metal salt is  $\text{CaCl}_2$ ,  $\text{MgCl}_2$  or  $\text{MgSO}_4$ .
28. The composition according to claim 26, wherein said sodium diclofenac is added to an aqueous suspension comprising said divalent metal salt, said water-swellaable polymer and said water.
29. The composition according to claim 1, further comprising benzalkonium chloride.
30. An ophthalmic composition comprising an aqueous suspension of a crosslinked carboxyl-containing polymer, solid diclofenac in free-acid form, dissolved diclofenac, and dissolved  $\text{Mg}^{++}$  or  $\text{Ca}^{++}$  cations in an amount of from about 1 to 5 times the stoichiometric equivalent amount per mole of said solid diclofenac; said composition having a pH of from about 4.0 to about 6.7 and the total amount of diclofenac being a pharmaceutically effective amount and said solid diclofenac comprising 85 to 95 mol% of the total amount of diclofenac.
31. The composition according to claim 30, further comprising 0.03 to 0.3 wt.% sodium perborate, 0.003 to 0.03 wt.% polyphosphonic acid peroxy stabilizer and 0.01 to 0.1 wt.% EDTA.


32. The composition according to claim 31, wherein said sodium perborate is contained in an amount of about 0.28 wt.% and said polyphosphonic acid peroxy stabilizer is diethylene triamine penta(methylene-phosphonic acid).

33. A preserved ophthalmic composition comprising water, about 0.01 to 0.5 wt.% of a perborate salt, about 0.001 to 0.06 wt.% of a polyphosphonic acid peroxy stabilizer, and about 0.01 to 0.1 wt.% of ethylenediaminetetraacetic acid.

34. The composition according to claim 33, wherein said water is sterile water, said perborate is sodium perborate contained in an amount of from 0.03 to 0.3 wt.%, and said polyphosphonic acid peroxy stabilizer is a compound of formula I or II:



wherein x is an integer of 0 to 3 and k, m, n, o, and p are each independently an integer of 1 to 4;



wherein q, r, s, and t are each independently an integer of 0 to 4.




FIG.1

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/10506

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K33/06 A61K31/38 A61K31/195 A61K31/19 A61K9/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE WPI Section Ch, Week 8347 Derwent Publications Ltd., London, GB; Class B05, AN 83-823242 XP002078183 &amp; JP 58 174309 A (WAKAMOTO PHARM CO LTD) , 13 October 1983 cited in the application see abstract</p>	1-31
Y	<p>WO 95 31968 A (INSITE VISION INC) 30 November 1995 cited in the application see page 8, paragraph 1 see tables 4,5 see claims</p>	1-31

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 September 1998

Date of mailing of the international search report

30/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/10506

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 21-25  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim(s) 21-25 is(are) directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/10506

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9531968 A	30-11-1995	AU 695699 B	20-08-1998
		AU 2552995 A	18-12-1995
		EP 0764018 A	26-03-1997
		JP 10500684 T	20-01-1998
<hr/>			